XBiotech Announces Phase I/II Study Results Of Xilonix Anti-tumor Therapy
Sunday, April 20, 2014 - 21:50
in Health & Medicine
XBiotech, a company involved in commercializing biological therapies, has published the results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston. The study describes the outcome in 52 advanced cancer patients treated with their Xilonix™ non-cytotoxic, anti-tumor therapy. The so-called true human antibody therapy was reported to have an excellent safety profile and the report describes comprehensive measures of patient performance during therapy with Xilonix. read more